Relapse/Refractory Multiple Myeloma Clinical Trial
Official title:
Open-label Phase I, Multi-center Study to Determine the Recommended Dose of CYAD-211 After a Non-myeloablative Preconditioning Chemotherapy in Multiple Myeloma Patients With Relapsed or Refractory Disease
The purpose of the IMMUNICY-1 study is to assess the safety, activity and cell kinetics of CYAD-211 in adults with relapsed or refractory multiple myeloma after a lymphodepletion regimen with fludarabine and/or cyclophosphamide
This study aims to determine the recommended dose of the allogeneic CYAD-211 (anti-BCMA CAR-T) cells after a non-myeloablative preconditioning chemotherapy in multiple myeloma (MM) patients with relapsed or refractory disease. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03944057 -
A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma
|
Phase 2 | |
| Recruiting |
NCT06084962 -
A Study of DeepTag-GPRC5D Targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT03353545 -
Retrospective and Prospective Study of POmalidomide Plus LoW Dose Dexa Efficacy in RRMM Patients Under Real-Life Conditions
|
||
| Withdrawn |
NCT02985333 -
Paclitaxel,Cyclophosphamide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
|
Phase 2 | |
| Withdrawn |
NCT02986451 -
Clarithromycin,Lenalidomide and Dexamethasone for Relapsed/Refractory Myeloma
|
Phase 2 | |
| Completed |
NCT02290431 -
Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma
|
Phase 2 |